FDAsafety guidance66% confidence
Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd. - 731020 - 07/10/2026
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Sunshine Lake Pharma; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Diabetes · Insulin
- Sub-indication
- General
Related signal: FDA Accepts Application for Langlara (Insulin Glargine-Aldy) by Sunshine Lake Pharma